U.S. markets closed
  • S&P 500

    3,901.82
    +90.67 (+2.38%)
     
  • Dow 30

    31,535.51
    +603.14 (+1.95%)
     
  • Nasdaq

    13,588.83
    +396.48 (+3.01%)
     
  • Russell 2000

    2,275.32
    +74.27 (+3.37%)
     
  • Crude Oil

    60.28
    -0.36 (-0.59%)
     
  • Gold

    1,722.50
    -0.50 (-0.03%)
     
  • Silver

    26.60
    -0.08 (-0.29%)
     
  • EUR/USD

    1.2051
    -0.0036 (-0.30%)
     
  • 10-Yr Bond

    1.4460
    -0.0140 (-0.96%)
     
  • GBP/USD

    1.3925
    +0.0003 (+0.02%)
     
  • USD/JPY

    106.8610
    +0.3590 (+0.34%)
     
  • BTC-USD

    49,773.19
    +4,520.17 (+9.99%)
     
  • CMC Crypto 200

    982.63
    +54.40 (+5.86%)
     
  • FTSE 100

    6,588.53
    +105.10 (+1.62%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

Has Kala Pharmaceuticals (KALA) Outpaced Other Medical Stocks This Year?

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Kala Pharmaceuticals (KALA) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of KALA and the rest of the Medical group's stocks.

Kala Pharmaceuticals is one of 895 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. KALA is currently sporting a Zacks Rank of #2 (Buy).

Over the past three months, the Zacks Consensus Estimate for KALA's full-year earnings has moved 10.92% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

Based on the latest available data, KALA has gained about 140.11% so far this year. In comparison, Medical companies have returned an average of -11.98%. As we can see, Kala Pharmaceuticals is performing better than its sector in the calendar year.

Breaking things down more, KALA is a member of the Medical - Biomedical and Genetics industry, which includes 384 individual companies and currently sits at #27 in the Zacks Industry Rank. Stocks in this group have lost about 7.33% so far this year, so KALA is performing better this group in terms of year-to-date returns.

Going forward, investors interested in Medical stocks should continue to pay close attention to KALA as it looks to continue its solid performance.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Kala Pharmaceuticals, Inc. (KALA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research